NCT00595101 is a Phase 2 clinical trial of PF-03187207 in Primary Open Angle Glaucoma, sponsored by Bausch & Lomb Incorporated.

Who is sponsoring NCT00595101?

NCT00595101 is sponsored by Bausch & Lomb Incorporated.

What drugs are being tested in NCT00595101?

Interventions in NCT00595101: PF-03187207, Latanoprost 0.005%, PF-03187207 Vehicle, Latanoprost Vehicle.

What condition does NCT00595101 study?

NCT00595101 studies Primary Open Angle Glaucoma, Ocular Hypertension.

Is NCT00595101 still recruiting?

NCT00595101 is currently completed. Last updated 10 September 2020.

Are results published for NCT00595101?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2020-09-10 · How we verify

NCT00595101

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Phase 2, 28-Day Parallel-Group, Double-Masked, Dose Finding Study Comparing The Safety And Efficacy Of PF-03187207 To Latanoprost In Patients With Primary Open Angle Glaucoma Or Ocular Hypertension.

Completed Phase 2 Results posted Last updated 10 September 2020

What this trial tests

Phase 2 trial testing PF-03187207 in Primary Open Angle Glaucoma in 117 participants. Completed in 1 June 2008.

Timeline

1 December 2007

Primary endpoint
1 June 2008

1 June 2008

Quick facts

Lead sponsor	Bausch & Lomb Incorporated
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	117
Start date	1 December 2007
Primary completion	1 June 2008
Estimated completion	1 June 2008
Sites	13 locations across Japan

Drugs / interventions tested

PF-03187207 — full drug profile →
Latanoprost 0.005% — full drug profile →
PF-03187207 Vehicle — full drug profile →
Latanoprost Vehicle — full drug profile →

Conditions studied

Primary Open Angle Glaucoma — all drugs for Primary Open Angle Glaucoma →
Ocular Hypertension — all drugs for Ocular Hypertension →

Sponsor

Bausch & Lomb Incorporated — full company profile →

Who can join

20 and older, any sex, with Primary Open Angle Glaucoma or Ocular Hypertension. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Change From Baseline Mean Diurnal Intraocular Pressure (IOP) in the Study Eye on Day 28
Time frame: Baseline, 28 days
Intraocular pressure (IOP) was measured using a Goldmann applanation tonometer. Diurnal IOP, defined as the mean IOP over the day based on values obtained at 8 AM, 10 AM, 1 PM, and 4 PM, was calculated for each visit. Both eyes were tested, with the right eye preceding the left eye. The operator initially set the dial at 10 mmHg, then looked through the slit lamp and adjusted the dial to take the

Sponsor's own description

To investigate dose response, safety and efficacy of PF-03187207 in patients with primary open-angle glaucoma or ocular hypertension

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Novel ocular antihypertensive compounds in clinical trials.
Chen J, Runyan SA, Robinson MR. · · 2011 · cited 71× · PMID 21629573 · DOI 10.2147/opth.s15971
Critical evaluation of latanoprostene bunod in the treatment of glaucoma.
Garcia GA, Ngai P, Mosaed S, Lin KY. · · 2016 · cited 30× · PMID 27799730 · DOI 10.2147/opth.s103985

Verify or expand the search:

Other recruiting trials for Primary Open Angle Glaucoma

Currently open trials in the same condition.

NCT07390890 — DSLT for Reducing Medication in Glaucoma · recruiting
NCT07447011 — Glaucoma Respsosne to Lifestyle Corrections in Sleep Apnea · NA · recruiting
NCT07358650 — Clinical Study Evaluating the Safety and Performance of the MIST Device for Intraocular Pressure Reduction in Patients W · NA · recruiting
NCT06948773 — A Study of the Helix Surgical System in Primary Open-Angle Glaucoma (POAG) and Cataract (HELIX) · NA · recruiting
NCT05439161 — XEN Glaucoma Gel Stent Versus Trabeculectomy · NA · recruiting

Other Bausch & Lomb Incorporated trials

Trials by the same sponsor.

NCT07054606 — A Study to Evaluate Concomitant Perfluorohexyloctane Use With Contact Lens Wear · Phase 4 · completed
NCT06803654 — A Study Comparing the Efficacy and Safety of Brimonidine Tartrate Ophthalmic Solution 0.025% With Sodium Hyaluronate Rel · Phase 3 · completed
NCT06594185 — A Study to Evaluate Real World Outcomes of the enVista® Aspire (EA) and Aspire Toric (ETA) Intraocular Lens in Subjects · NA · completed
NCT06479148 — Clinical Evaluation of the Performance of the enVista® Aspire™ (EA) Lens · NA · terminated
NCT06333028 — A Study to Evaluate the enVista® Aspire (EA) Intraocular Lens in Subjects Undergoing Cataract Extraction · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00595101 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Bausch & Lomb Incorporated
Last refreshed: 10 September 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00595101.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing